Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3323 ARTÍCULOS , VIENDO DEL 3046 AL 3060

Assessing executive function in Parkinson disease: the alternating names test. Part I. Reliability, validity, and normative data

Hyde T, Fritsch T.

Parkinsonism Relat Disord. 2011 Feb;17(2):100-5. doi: 10.1016/j.parkreldis.2010.08.023. Epub 2010 Nov 30.

Longevity analysis of currently available deep brain stimulation devices

Halpern CH, McGill KR, Baltuch GH, Jaggi JL.

Stereotact Funct Neurosurg. 2011;89(1):1-5. doi: 10.1159/000321710. Epub 2010 Dec 1.

SPECT imaging evaluation in movement disorders: far beyond visual assessment

Badiavas K, Molyvda E, Iakovou I, Tsolaki M, Psarrakos K, Karatzas N.

Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):764-73. doi: 10.1007/s00259-010-1664-1. Epub 2010 Dec 2.

Untreated depressive symptoms among cognitively-intact, community dwelling Filipino patients with Parkinson disease

Go CL, Rosales RL, Joya-Tanglao M, Fernandez HH.

Int J Neurosci. 2011 Mar;121(3):137-41. doi: 10.3109/00207454.2010.537414. Epub 2010 Dec 2.

The contributions of antioxidant activity of lipoic acid in reducing neurogenerative progression of Parkinson's disease: a review

De Araújo DP, Lobato Rde F, Cavalcanti JR, Sampaio LR, Araújo PV, Silva MC, Neves KR, Fonteles MM, Sousa FC, Vasconcelos SM.

Int J Neurosci. 2011 Feb;121(2):51-7. doi: 10.3109/00207454.2010.535934. Epub 2010 Dec 2.

Millimolar Mn2+ influences agonist binding to 5-HT1A receptors by inhibiting guanosine nucleotide binding to receptor-coupled G-proteins

Parkel S, Tõntson L, Rinken A.

Neurotoxicology. 2011 Jan;32(1):25-30. doi: 10.1016/j.neuro.2010.11.005. Epub 2010 Nov 30.

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

Citrome L.

Int J Clin Pract. 2011 Feb;65(2):189-210. doi: 10.1111/j.1742-1241.2010.02587.x. Epub 2010 Dec 3.

Correlates of constipation in people with Parkinson's

Gage H, Kaye J, Kimber A, Storey L, Egan M, Qiao Y, Trend P.

Parkinsonism Relat Disord. 2011 Feb;17(2):106-11. doi: 10.1016/j.parkreldis.2010.11.003. Epub 2010 Dec 3.

Between destiny and disease: genetics and molecular pathways of human central nervous system aging

Glorioso C, Sibille E.

Prog Neurobiol. 2011 Feb;93(2):165-81. doi: 10.1016/j.pneurobio.2010.11.006. Epub 2010 Dec 2.

Preexcitation unmasks J waves: 2 cases

Nagao S, Hayashi Y, Yagihara N, Sato A, Watanabe H, Furushima H, Chinushi M, Aizawa Y.

J Electrocardiol. 2011 May-Jun;44(3):359-62. doi: 10.1016/j.jelectrocard.2010.09.004. Epub 2010 Dec 3.

Iron overload triggers redox-sensitive signals in human IMR-32 neuroblastoma cells

Salvador GA, Oteiza PI.

Neurotoxicology. 2011 Jan;32(1):75-82. doi: 10.1016/j.neuro.2010.11.006. Epub 2010 Dec 3.

Modeling neurodegenerative disease pathophysiology in thiamine deficiency: consequences of impaired oxidative metabolism

Jhala SS, Hazell AS.

Neurochem Int. 2011 Feb;58(3):248-60. doi: 10.1016/j.neuint.2010.11.019. Epub 2010 Dec 3.

Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field

Ambermoon P, Carter A, Hall WD, Dissanayaka NN, O'Sullivan JD.

Addiction. 2011 Feb;106(2):283-93. doi: 10.1111/j.1360-0443.2010.03218.x. Epub 2010 Dec 7.

Using the WHOQOL-DIS to measure quality of life in persons with physical disabilities caused by neurodegenerative disorders

Lucas-Carrasco R, Pascual-Sedano B, Galán I, Kulisevsky J, Sastre-Garriga J, Gómez-Benito J.

Neurodegener Dis. 2011;8(4):178-86. doi: 10.1159/000321582. Epub 2010 Dec 3.

Does the clinical practice guideline on Parkinson's disease change health outcomes? A cluster randomized controlled trial

Larisch A, Reuss A, Oertel WH, Eggert K.

J Neurol. 2011 May;258(5):826-34. doi: 10.1007/s00415-010-5848-1. Epub 2010 Dec 7.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias